Abstract 461P
Background
Lung cancer is the leading cause of cancer deaths worldwide including in India. Around 80% of these are Non Small Cell Lung Cancers (NSCLC) detected in advanced stages where surgical resection is not an option and locally advanced stage patients are treated with concurrent chemoradiotherapy.
Methods
A total of 90 patients of NSCLC Stages IIIA and IIIB participated in the study conducted over the last eighteen months. They were randomized and distributed between two arms in 1:1 ratio. Their pre-treatment Pulmonary Function Tests were recorded. Participants in Arm A underwent 30 minutes of yoga session daily besides standard fractionation radiotherapy with concurrent weekly chemotherapy. Participants in Arm B received the same schedule of concurrent chemoradiotherapy but without the daily yoga session. Their post-treatment Pulmonary Function Tests were recorded at six weeks post completion of chemoradiotherapy and compared with pre-treatment values.
Results
21 participants in Arm A recorded positive changes in their FEV1 values, compared to just 3 patients in Arm B (p=0.0002), suggesting daily yoga sessions during treatment can actually help in improvement of lung function among locally advanced NSCLC patients.
Conclusions
Further multi-institutional studies with more participants should be encouraged and yoga be more maistreamed and formally incoporated into standard therapeutic regimens for the management of locally advanced non small cell lung cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract